The 2026 ACC/AHA clinical guidelines provide an updated framework for the evaluation and management of dyslipidemia.
This synopsis summarizes the 2026 ACC/AHA clinical practice guidelines for the evaluation and management of dyslipidemia.
Absolute Event Rate: 0% vs 0%
This JAMA Clinical Guidelines Synopsis summarizes the 2026 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on management of dyslipidemia.
“The significant cardiovascular benefits with more intensive lowering of LDL-C to <55 mg/dL in patients without previous MI or stroke in VESALIUS-CV now blur the distinction between ASCVD risk categories when defining a 'goal' LDL-C value. Thus, future updates to the 2026 ACC/AHA Dyslipidemia Guideline should include a single pathway of care for all patients with ASCVD … with an optimal LDL-C goal of <55 mg/dL to be achieved via pharmacotherapy as well as lifestyle optimization.”
Saeed et al. (Mon,) reported a other. The 2026 ACC/AHA clinical guidelines provide an updated framework for the evaluation and management of dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: